Resume

Medical Development

Location:

Denver, CO, 80238

Posted:

February 08, 2013

Contact this candidate

Resume:

Yingnian Lu, MS

**** ***** **,

Denver, CO. ***38

Tel: 303-***-****

E-mail: aboanb@r.postjobfree.com

Summary

In my over 13-year career in biomedical research in academia and biotech industry, I planned and executed multiple programs in whole yeast-based immunotherapeutic vaccine research and development. My accomplishments included vaccine designing, engineering and testing the efficacy both in animal models and in immunology assays. I played the leading roles in the cancer therapeutic series products that target mutant Ras protein in lung carcinoma model and EGFR in glioblastoma model. The pre-clinical data I generated is reflected in the key publications and patents.

I am a self-motivated, energetic, and a team player with an easy-going personality. I am adept at a fast paced work environment and enjoy challenges.

Professional Experience

Research Scientist 2003-Oct, 2012

GlobeImmune Inc. (Louisville, CO)

• Conducted vaccine designing, engineering, validating, and potency testing to build a product pipeline.

• Generated pivotal efficacy data in animal tumor models that were included in several IND filings.

• Invented new methods for genotyping and potency testing to support the company's clinical trials.

• Led projects in cancer vaccine products targeting mutant Ras protein and EGFR.

• Supervised two direct reports.

These accomplishments involved the following activities:

Molecular/cellular biology: gene construction and expression in E.coli/yeast/mammalian cell; recombinant protein purification; RNA isolation and gene expression by qRT-PCR; Hybridizations (DNA, RNA probes, in situ RNA hybridization, Southern Blot, Northern Blot); ex vivo cell manipulations (primary cell culture, differentiation, proliferation and proliferation inhibition assay); tumor line gene transfection and transduction

Immunology: in vitro and in vivo antigen dependent killing assays; lymphocyte proliferation assays; cell labeling/staining for FACS/Guava and microscopic analysis; Immunohistochemistry; immunoassay development (ELISA, ELISpot, immunoblot, immunoprecipitation)

Animal modeling: IACUC protocol designing and executing in tumor and viral model; substantial skills in small animal manipulations –vaccine dosing (SC, PO, IP, IV, IN), sampling (blood, spleen, lymph node, visceral fat tissue); tissue/organ dissection; tumor challenging and monitoring; drug label and distribution by PET imaging (rat model); skin/adipose tissue biopsy (innovative method approved by IACUC);intracranial surgery.

Genotyping: de novo development of genotyping methods (introducing peptide-nucleic acid clamping genotyping); establishment of a novel melting curve-based technology (patent submitted)

Manufacturing and QC: master strain banking under cGMP; batch release testing development including protein immunoprecipitation for Mass Spectrometry, protein content quantification, total yeast protein assay and plasmid copy number

Virology: retroviral and lentiviral vector constructions; virus production, titration, tumor line and primary cell transduction (transient & stable line); adenovirus production (large scale), purification, titration, neutralization antibody plaque assay.

Calor Therapeutics (Denver, CO) 2010

• Developed project for proof-of-concept of PRDM16 modulates brown adipose cell development from adipose-derived stem cells (ASC) against obesity: Mouse ASC isolation, differentiation, phenotyping (morphology, UCP1 gene expression and oxygen consumption assay) and transplantation.

Research Associate 1999-2003

University of Colorado Health Sciences Center (Dr. Franzusoff lab)

• Established of PC6B gene knockout model:

target vector construction, mouse embryonic stem cell culture, homozygous recombinants identification, colony breeding, phenotyping

• Developed a novel therapeutic vaccine for brain and lung cancer and tested in animal models.

• Conducted Human PC6A gene cloning: 5’ & 3’RACE

Academic Positions 1985-1999

Qingdao University Medical College

• Associate professor, Associate director of Dept. of Clinical Immunology 1997-1999

• Lecturer, Dept. of Clinical Immunology 1991-1997

• Teaching Assistant, Dept. of Clinical Immunology 1985-1988

Education

Qingdao University Medical College. Qingdao, China. 1988-1991

M.S. in Medical Microbiology and Immunology

Qingdao University Medical College. Qingdao, China. 1980-1985

Bachelor of Medicine, Clinical Medicine

Patents

1. “Compositions and Methods for the Treatment or Prevention of Adenovirus-36 Infection” Apelian, King, Coeshott, Lu. PCT Publication No. WO 2012/083302, published June 21, 2012.

2. “Yeast-based Vaccine for Inducing an Immune Response” Duke, Franzusoff, Haller, King, Lu, Hodson. U.S. Patent No. 7,736,642, issued June 15, 2010.

3. “Ras Mutation & Compositions & Methods Related Thereto” Guo, Lu, Bellgrau, Franzusoff. U.S. Patent No. 7,745,128, issued June 29, 2010.

4. “Genotyping Method and Kit” Lu, King, Britton, Guo & Franzusoff, PCT Publication No. WO 2010/065626, published June 10, 2010.

Publications

1. Munson S, Parker, J, King T, Lu Y, Kelley V,Guo Z, Borges V,Franzusoff A.(2008), Coupling innate and adaptive immunity with yeast-based cancer immunotherapy; chapter 9 in Cancer Vaccines and Tumor Immunity, R. Orentas, B.D. Johnson and J.W. Hodge, eds, John Wiley & Sons, Inc, N.Y. pp.131-149.

2. Haller AA, King T, Kemmler C, Lu Y, Franzusoff A, Bellgrau D, Rodell TC, Duke RC (2007), Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins; Vaccine. 25: 1452-1463.

3. Franzusoff A, Duke RC, King T, Lu Y, Rodell TC. (2005), Yeasts encoding tumor antigens in cancer immunotherapy.Expert Opin. Biol. Ther. 5: 565-575.

4. Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Duke RC, RodellTC,Franzusoff A. (2004), Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Research. 64: 5084-5088.

5. Qi L, Singh RP, Lu Y, Franzusoff A, Agarwal R, Harrison GS Glodé LM. (2003), Epidermal growth factor receptor mediates silibinin-induced cytotoxicity in a rat glioma cell line.Cancer Biol. Ther. 2: 526-531.

Selected Abstracts

1. Z.Guo, C.Kemmler, D.Mann, Y.Lu, C.Coeshot, D.Apelian, M.Subramanian, U.Lopatin, W.Delaney, T.King. Recombinant yeast therapeutic vaccines expressing hepatitis B virus (HBV) X, S, and core antigens generate antigen specific T cell responses and tumor protection in mice. AASLD Abstract 1424277, Nov. 2012.

2. Amber Britton, Sarah Oakes, Zhimin Guo, Yingnian Lu, Sue Speyer, Thomas King, Alex Franzusoff and David Apelian, Prospective use of an optimized ras mutation diagnostic in an adjuvant Phase 2 trial of mutation specific Ras-targeted immunotherapy (GI-4000) in pancreas cancer. AACR, April 2009.

3. Alex Franzusoff, Zhimin Guo, Yingnian Lu, Sarah Oakes, Amber Britton, Valerie Fiolkoski, Thomas King, Deborah Quick, John Frenz and David Apelian. Prevalence of G12R or Q61H K-Ras mutations in pancreas cancer and development of Ras-targeted immunotherapy. AACR-NCI_10-21-08.

4. Zhimin Guo, Yingnian Lu, Sarah Oakes, Amber Britton, Thomas King, Kai-wen Huang, Vesela Tzenova, John Ferraro, David Apelian and Alex Franzusoff, Transnational patterns of pancreas cancer ras mutations and discovery of a new ras mutation with oncogenic synergy when found with ras codon 12 mutations. AACR-EORTC_2008.

5. Zhimin Guo, Sarah Oakes, Yingnian Lu, Michio Sugita, Wilbur Franklin & Alex Franzusoff. Ocogenic synergy and newly identified transforming Ras mutation in human cancer. AACR 2007.

6. Yingnian Lu, Don Bellgrau, Tim Rodell, Scott Cruickshank, Alex Franzusoff. Yeast-Based Tarmogen immununotherapy again brain tumor express self antigen. AACR-EGFR_4-2-06.

7. A. Haller, T.King, Y.Lu, C. Kemmler, G.Gordon, D.Bellgrau, A.Franzusoff, T.Rodell, R.Duke. A novel yeast-based immunotherapeutic product for chronic hepatitis C virus infection. AASLD HCV Poster March 2005.

8. Mayumi Fujita, Helge Riemann, Joe Takao, Yingnian Lu, David A Norris, Donald Bellgrau, Alex Franzusoff. Whole recombinant yeast immunotherapeutic vaccine expressing human Mart-1 elicits protection against melanoma. Keysone Symposia 2005.

9. A. Haller, T. King, Y.Lu, C. Kemmler, G. Gordon, D. Bellgrau, A. Franzusoff, T.Rodell, R. Duke. Preclinical development of yeast-based immunotherapy for chronic hepatitis C virus infections. 8th Conference on Vaccine Research Poster 5-9-05.

10. Mayumi Fujita, Joe Takao, Yingnian Lu, David A Norris, Donald Bellgrau, Alex Franzusoff. Whole recombinant yeast immunotherapeutic protection against melanoma. Cancer Vaccine abstract (P-25) 2004.

11. Donald Bellgrau, Yingnian Lu, Al Malkinson, Lori Nield, Richard Duke, Tim Rodell, Sibyl Munson, Alex Franzusoff. Whole recombinant yeast-based immunotherapy targeting self or mutated self tumor antigens for the treatment of solid tumors. AACR, vol.45:571, March 2004.

References

Thomas H. King, Ph.D.

Director, Research and Development

GlobeImmune, Inc.

303-***-**** Office

303-***-**** Cell

aboanb@r.postjobfree.com

David Apelian, MD, PhD, MBA

Sr. Vice President of Research and Development

Chief Medical Officer

GlobeImmune, Inc.

720-***-**** Cell